Get the Stockscreener App
11.38
2.15%
+0.24
After Hours:
11.38
Third Harmonic Bio Inc stock is currently priced at $11.38, with a 24-hour trading volume of 151.37K.
It has seen a +2.15% increased in the last 24 hours and a +30.06% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $11.18 pivot point. If it approaches the $11.55 resistance level, significant changes may occur.
Previous Close:
$11.14
Open:
$11.26
24h Volume:
151.37K
Market Cap:
$463.81M
Revenue:
-
Net Income/Loss:
$-30.82M
P/E Ratio:
-7.2401
EPS:
-1.5718
Net Cash Flow:
$-20.43M
1W Performance:
+0.44%
1M Performance:
+30.06%
6M Performance:
+75.08%
1Y Performance:
+128.97%
1D Range:
$10.91
$11.53
52W Range:
$4.31
$12.42
Third Harmonic Bio Inc Stock (THRD) Company Profile
Name
Third Harmonic Bio Inc
Sector
Industry
Phone
617-915-6680
Address
300 Technology Square, 8th Floor, Cambridge
Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-22 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-22 | Initiated | Cowen | Outperform |
| Oct-10-22 | Initiated | Jefferies | Buy |
| Oct-10-22 | Initiated | Morgan Stanley | Overweight |
Third Harmonic Bio Inc Stock (THRD) Latest News
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
GlobeNewswire Inc.
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire Inc.
Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference
GlobeNewswire Inc.
Are You Looking for a Top Momentum Pick? Why Third Harmonic Bio, Inc. (THRD) is a Great Choice
Zacks Investment Research
Third Harmonic Bio Announces Third Quarter 2023 Financial Results
GlobeNewswire Inc.
Third Harmonic Bio Inc Stock (THRD) Financials Data
Third Harmonic Bio Inc (THRD) Net Income 2024
THRD net income (TTM) was -$30.82 million for the quarter ending December 31, 2023, a +12.32% increase year-over-year.
Third Harmonic Bio Inc (THRD) Cash Flow 2024
THRD recorded a free cash flow (TTM) of -$20.43 million for the quarter ending December 31, 2023, a +41.50% increase year-over-year.
Third Harmonic Bio Inc (THRD) Earnings per Share 2024
THRD earnings per share (TTM) was -$0.95 for the quarter ending December 31, 2023, a +41.07% growth year-over-year.
Third Harmonic Bio Inc Stock (THRD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Holles Natalie C. | CEO |
Apr 11 '24 |
Sale |
12.19 |
13,558 |
165,214 |
1,218,836 |
| Person Julie | CHIEF ADMINISTRATIVE OFFICER |
Apr 04 '24 |
Option Exercise |
4.20 |
1,107 |
4,649 |
1,107 |
| Person Julie | CHIEF ADMINISTRATIVE OFFICER |
Apr 04 '24 |
Sale |
10.00 |
1,107 |
11,070 |
0 |
| Person Julie | Chief Administrative Officer |
Dec 05 '23 |
Option Exercise |
4.20 |
12,863 |
54,025 |
12,863 |
| Conner Edward R. | Chief Medical Officer |
Dec 05 '23 |
Option Exercise |
4.20 |
4,790 |
20,118 |
4,790 |
| Person Julie | Chief Administrative Officer |
Dec 05 '23 |
Sale |
10.30 |
12,863 |
132,484 |
0 |
| Conner Edward R. | Chief Medical Officer |
Dec 05 '23 |
Sale |
10.03 |
4,790 |
48,062 |
0 |
About Third Harmonic Bio Inc
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
3.18%
Cap:
|
Volume (24h):